• Therapeutic Control of Aspirin-Exacerbated Respiratory Disease
If you have Samter’s Triad or Aspirin Exacerbated Respiratory Disease (AERD) and would like to undergo an aspirin desensitization to help treat your symptoms, you may be eligible for a research study at the Brigham and Women’s Hospital testing a new approach to treatment of AERD. This research study uses a medication that is approved by the Food and Drug Administration (FDA) but not to treat asthma or AERD. The medication, prasugrel (Effient®), is an inhibitor of platelets, which we believe play a role in AERD. To qualify for the study, you have to be 18-65 years old, have symptoms consistent with Samter’s Triad/AERD, and have asthma. The study involves 5 visits over a 23 week period and involves two aspirin desensitization procedures, blood sampling, and urine tests. You will be seen by a medical doctor and will receive the study medication at no cost. The purpose of the study is to find out if taking prasugrel will help to treat the symptoms of AERD and prevent reactions to aspirin, and to learn why aspirin desensitization improves the respiratory symptoms of patients with AERD. Compensation is up to $462. For more information, please contact the Asthma Research Center at 1-888-99-ASTHMA or Dr. Tanya Laidlaw at tlaidlaw@partners.org.
Institution  –  BWH - Brigham and Women's Hospital, Boston, MA
Principal Investigator  – Elliot Israel
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Jillian Bensko
Email  – jbensko@partners.org
Phone  – 617-732-6641